Can-Fite BioPharma Ltd.
About Can-Fite BioPharma Ltd.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $405.0K
- Net income
- -$9.8M
- Total assets
- $9.5M
- Market cap
- $6.6M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $6.6M
- Shares outstanding
- 2.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 10, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.8M in FY2025.
- Trading 88% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Can-Fite BioPharma Ltd..
Write a review
News about Can-Fite BioPharma Ltd.
News & sentiment via Polygon.io
